CCO Annual Update
HIV/AIDS Annual Update 2002
Viral Pathogenesis: HIV Attachment and Entry
|
Module 1 of 11
|
Program Director:
John P. Phair, MD
|
|
 Topics covered include:
- Introduction
- Basic Entry Process
- The First Step: Virus Attachment
- The Second Step: CD4 Binding
- The Third Step: Coreceptor Binding
Learning Objectives
Upon completion of this activity, participants should be able to:
|
Immunopathogenesis and Immune Reconstitution
|
Module 2 of 11
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- HIV-Specific Immunity
- CD4+ T-Cell Depletion
- Therapeutic Manipulation of the Immune System
- Summary—Implications for Clinical Practice
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the functional capacity of immune reconstitution Discuss the kinetics of immune reconstitution Describe the extent and limitations of reconstitution of immunity with HAART
|
Treatment Strategies for Antiretroviral-Experienced Patients
|
Module 3 of 11
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- The Goal of Initial Therapy
- Defining Treatment Failure
- Responding to Failure
- Changing Therapy
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the potential value and risks of structured treatment interruptions in patients with stable CD4+ cell counts. List the benefits of continuing a virologically failing antiretroviral regimen for reasons of viral fitness. Review the potential utility of pharmacokinetic manipulation in patients on failing antiretroviral regimens.
|
Entry Inhibitors
|
Module 4 of 11
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Interaction of Gp120 With the CD4 Molecule
- Inhibitors of Gp120-CD4 Interaction
- Interaction of Gp120 With Chemokine Receptors
- CCR5 and CXCR4 Inhibitors
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the mechanisms by which resistance to entry inhibitors develops. Outline the mechanisms of action of HIV-1 inhibitors. Describe the antiretroviral activity, mechanism of delivery, and potential side-effects of entry inhibitors in clinical development.
|
Resistance: From Bench to Bedside
|
Module 5 of 11
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Molecular Basis for Resistance in the HIV-1 Reverse Transcriptase
- Insights Into Mechanisms of Drug Failure and Resistance
- Relevance of Specific Mutations in HIV to Clinical Antiretroviral Resistance
- Interpretation of Resistance Test Results
Learning Objectives
Upon completion of this activity, participants should be able to:
Explain the clinical utility of genotypic and phenotypic resistance detection assays State the molecular basis for resistance in the HIV-1 reverse transcriptase and protease enzymes Describe the relevance of specific mutations in the HIV-1 genome to clinical antiviral resistance
|
Pathogenesis & Epidemiology of Metabolic Abnormalities
|
Module 6 of 11
|
Program Director:
John P. Phair, MD
- Judith S. Currier, MD, MSc
|
|
|
Topics covered include:
- Introduction
- Lipid and Glucose Abnormalities
- New Data on the Effects of Antiretroviral Agents on Lipids
- Mechanisms of PI Effects on Triglycerides and Cholesterol
- Direct Effects of Antiretroviral Agents on Glucose Metabolism
Learning Objectives
Upon completion of this activity, participants should be able to:
Define the direct effects of antiretroviral agents upon glucose and lipid metabolism Review the epidemiology of metabolic abnormalities (glucose, lipids, andbody shape changes) in HIV infection Describe the purported nondrug mechanisms promoting metabolic complications
|
Screening And Prevention For Cardiovascular Complications In The HAART Era
|
Module 7 of 11
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Epidemiology of Cardiovascular Disease in the HAART Era
- Determining Vascular Risk in Patients Without Cardiac Symptoms
- Overview of NCEP ATP III Guidelines
- Framingham-Based Risk Assessment: Special Considerations in HIV Patients
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the application of the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III guidelines to patients treated with HAART Review the epidemiology of cardiovascular disease in patients with HIV infection in the era of highly active antiretroviral therapy (HAART) Quantify absolute and relative cardiovascular risks based upon accepted risk factors Discuss the use of cardiovascular technologies for detecting subclinical atherosclerosis in patients with HIV infection
|
Mitochondrial Toxicity
|
Module 8 of 11
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Mechanisms of NRTI-Mediated Toxicity: Mitochondrial Toxicity and the "Pol-[T4 type='symbol' name='gamma' /]" Hypothesis
- In Vitro Studies: Establishing a Toxicity Profile of NRTIs
- Clinical NRTI-Induced Toxicity Syndromes: Evidence for Mitochondrial Involvement
- Monitoring NRTI-Associated Mitochondrial Toxicities
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the in vivo correlates of in vitro and observational studies of mitochondrial toxicity Discuss the mechanisms of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity Evaluate the value and use of clinical assays of mitochondrial dysfunction
|
Management of Morphologic Changes During Antiretroviral Therapy: Insights From Etiology
|
Module 9 of 11
|
Program Director:
John P. Phair, MD
 
- Christine Baldwin, BSc, Dip Diet
- Graeme Moyle, MD, MBBS
|
|
|
Topics covered include:
- Introduction
- Overview of Theories of Etiology
- Roles of PIs and NRTIs in the Etiology of Lipoatrophy
- Role of HIV-Mediated Immune Dysregulation in the Etiology of Lipoatrophy
- Management of Lipodystrophy: Diet and Exercise
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the role of antiretroviral therapy modification as a potential management tool for lipodystrophy Discuss possible etiologic factors that may be relevant to the management of lipodystrophy Review the results of studies of specific drug therapies for individual manifestations of lipodystrophy
|
AIDS-Related Malignancies in the Era of HAART
|
Module 10 of 11
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Etiology and Epidemiology of Kaposi's Sarcoma
- Treatment of AIDS-Related KS and The Role of HAART
- Current Treatment of Localized and Disseminated KS
- Pathogenesis-Based Therapies for KS
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss recently evaluated treatments for Kaposi's sarcoma and AIDS-related lymphoma List the ways in which HHV-8 may be transmitted Explain the changing epidemiology of AIDS-related malignancies in the HAART era
|
Screening for and Treatment of Anal Intraepithelial Neoplasia
|
Module 11 of 11
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Why Screen for AIN?
- Natural History of AIN
- Who Should Be Considered for AIN Screening?
- Current Approaches to Treatment of AIN
Learning Objectives
Upon completion of this activity, participants should be able to:
Understand current approaches to treatment of AIN Understand current challenges to implementation of routine anal cytology screening and treatment of AIN Understand the rationale for screening for anal intraepithelial neoplasia (AIN)
|
Animations
Fusion and Cell Entry
 |
|
This animation and others are available for use offline from the Download Library.
To download to your own computer and use for personal or teaching purposes, click here
Format: Adobe Flash | File size: 214 KB
|
Fusion Inhibition
|
|
This animation and others are available for use offline from the Download Library.
To download to your own computer and use for personal or teaching purposes, click here
Format: Adobe Flash | File size: 181 KB
|
Phase 3 Studies of T-20 in Salvage Theory
|
|
This animation and others are available for use offline from the Download Library.
To download to your own computer and use for personal or teaching purposes, click here
Format: Adobe Flash | File size: 71 KB
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|